Investor Overview

Satsuma Pharmaceuticals Investor Relations

Corporate Presentation
Recent News
Nov 26, 2019

South San Francisco, CA, November 26, 2019 – Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, Satsuma President and...

Nov 12, 2019

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today reported financial results for the...

Sep 17, 2019

Satsuma Pharmaceuticals, Inc. ("Satsuma" or the "Company") (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute...

Stock Info
NASDAQSTSA